Metformin’s Mechanism May Center on the Gut, Not the Liver

Metformin’s best-known effect may begin in the intestine

For decades, metformin has been understood as a medicine that mainly acts on the liver, where it helps suppress glucose production. That view has shaped both clinical teaching and the scientific search for why the drug works so reliably in type 2 diabetes. New research from Northwestern University now argues that the dominant site of action may be somewhere else entirely: the gut.

In a new study published in Nature Metabolism, researchers working in mice found that metformin appears to lower blood sugar primarily by altering energy use in intestinal cells. Instead of emphasizing the liver, the study points to the lining of the intestine as a major metabolic control point, one that may pull glucose out of the bloodstream by forcing those cells to consume more of it.

The finding does not change the fact that metformin is already one of the most widely used diabetes medicines in the world. What it does change is the biological story behind that success. If the team’s interpretation holds up, researchers may have to revisit a central assumption about one of medicine’s oldest and most important metabolic drugs.

What the study found

According to the Northwestern team, metformin slows mitochondrial energy production inside gut cells. Mitochondria are the structures that help cells convert nutrients into usable energy. In this case, reducing part of that energy-making process appears to push intestinal cells to metabolize additional glucose instead.

That matters because excess glucose in the bloodstream is a defining problem in diabetes and metabolic dysfunction. By increasing glucose use inside the intestine, metformin may reduce the amount of sugar circulating in blood after meals or during routine metabolism.

The researchers describe this as a shift in emphasis, not merely a minor detail. Their conclusion is that metformin “focuses primarily on the gut,” rather than the liver, to keep blood sugar from rising. In practical terms, the intestine may be acting as a sink for glucose that would otherwise remain in circulation.

Corresponding author Navdeep Chandel said the work suggests metformin helps the intestine “suck the glucose out of the bloodstream,” underscoring a larger point: the gut is not just a passive digestive organ, but an active regulator of blood sugar.

Why this matters for diabetes research

Metformin has been prescribed for years because it works, is relatively inexpensive, and is backed by extensive clinical use. Yet a drug’s broad effectiveness does not automatically mean its mechanism is fully understood. In that sense, this study reflects a recurring pattern in medicine, where long-used therapies remain scientifically unsettled even while they are clinically routine.

The Northwestern work builds on previous findings from the same lab that tied metformin’s glucose-lowering effect to blockage of mitochondrial complex I, a component of cellular respiration. The new study goes further by asking where that effect is most important in the body. Their answer is the gut.

If that answer proves robust beyond mouse models, it could influence how future diabetes treatments are designed. Instead of trying to achieve systemic effects throughout the body, drug developers may be able to target the intestine more directly. That could create therapies that preserve the useful metabolic effects of metformin while refining dosage, delivery, or side-effect profiles.

It also offers a more specific framework for understanding why the drug has remained so effective across millions of patients. A gut-centered explanation may help researchers sort which downstream effects are primary and which are secondary.

Reframing an old “wonder drug”

Metformin occupies a rare position in medicine. It is old enough to feel foundational, common enough to be familiar to nearly every endocrinologist, and versatile enough to be discussed far beyond diabetes alone. Source text for the new study describes it as a “wonder drug,” a label that reflects both its long history and the persistent interest in how much more it may still teach scientists.

The new findings do not diminish the liver’s role in glucose regulation. The liver remains central to how the body stores and releases sugar. But the study suggests the dominant trigger for metformin’s effect may have been assigned to the wrong tissue. That is a meaningful distinction because mechanistic precision shapes everything from follow-on drug development to how researchers interpret biomarkers and side effects.

First author Zach Sebo said the work shows value in revisiting settled assumptions. That is a useful reminder in a field where standard explanations can harden into doctrine even when the evidence remains incomplete. A better account of metformin’s action could sharpen basic metabolic science, not just therapeutic strategy.

Possible implications beyond metformin

The Northwestern team also linked the finding to a broader therapeutic idea: directing drugs or supplements to the gut might be an effective way to control blood sugar. That is a strategic statement as much as a biological one. If the intestine can be used as a controlled metabolic interface, it may become a more prominent target in next-generation diabetes care.

Such an approach could be relevant not only for metformin derivatives, but for entirely new classes of treatments aimed at intestinal energy use, nutrient sensing, or glucose handling. The source text also notes parallels with berberine, a compound often discussed in consumer health circles, suggesting researchers are increasingly interested in whether multiple glucose-lowering pathways converge in the gut.

That does not mean a new treatment class is imminent. This study was conducted in mice, and translation into human therapy is never automatic. But it does identify a plausible and experimentally grounded direction for future work.

What comes next

The immediate question is whether the same gut-first mechanism can be demonstrated clearly in humans. Mouse studies are essential for mechanistic biology, but they are not the final word on clinical medicine. Researchers will need to test whether intestinal cells in people respond the same way, whether this effect explains a substantial share of metformin’s benefit, and how it interacts with known variability among patients.

Even if the answer is more nuanced in humans, the paper appears to have moved the conversation. It offers a concrete alternative to the traditional liver-centered narrative and ties that alternative to cellular metabolism in a specific tissue.

For a drug as established as metformin, that is notable on its own. Scientific revisions are often associated with new molecules and flashy platforms, not with an inexpensive medicine that has already shaped global diabetes care for years. But mature therapies can still yield new biology. In this case, a familiar treatment may be opening a less familiar view of the intestine as a frontline regulator of blood sugar.

If that view holds, the impact will extend beyond a mechanistic footnote. It would reshape how researchers think about one of the most widely used metabolic drugs in the world and could redirect the search for future diabetes therapies toward the gut, where metformin may have been doing its most important work all along.

This article is based on reporting by Medical Xpress. Read the original article.